Annual FCF
-$18.10 M
-$504.90 K-2.87%
31 December 2023
Summary:
Inhibikase Therapeutics annual free cash flow is currently -$18.10 million, with the most recent change of -$504.90 thousand (-2.87%) on 31 December 2023. During the last 3 years, it has fallen by -$16.97 million (-1502.56%). IKT annual FCF is now -2631.37% below its all-time high of $715.00 thousand, reached on 31 December 2018.IKT Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$4.88 M
+$173.30 K+3.43%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly free cash flow is currently -$4.88 million, with the most recent change of +$173.30 thousand (+3.43%) on 30 September 2024. Over the past year, it has dropped by -$776.00 thousand (-18.90%). IKT quarterly FCF is now -6565.03% below its all-time high of $75.50 thousand, reached on 30 September 2020.IKT Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$17.24 M
-$776.00 K-4.71%
30 September 2024
Summary:
Inhibikase Therapeutics TTM free cash flow is currently -$17.24 million, with the most recent change of -$776.00 thousand (-4.71%) on 30 September 2024. Over the past year, it has increased by +$968.30 thousand (+5.32%). IKT TTM FCF is now -9676.02% below its all-time high of -$176.40 thousand, reached on 30 September 2020.IKT TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.9% | -18.9% | +5.3% |
| 3 y3 years | -1502.6% | -141.6% | -54.7% |
| 5 y5 years | -2631.4% | -10000.0% | -4904.3% |
IKT Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1502.6% | at low | -141.6% | +18.3% | -54.7% | +13.0% |
| 5 y | 5 years | -2631.4% | at low | -6565.0% | +18.3% | -9676.0% | +13.0% |
| alltime | all time | -2631.4% | at low | -6565.0% | +18.3% | -9676.0% | +13.0% |
Inhibikase Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.88 M(-3.4%) | -$17.24 M(+4.7%) |
| June 2024 | - | -$5.05 M(+30.7%) | -$16.47 M(+3.0%) |
| Mar 2024 | - | -$3.87 M(+12.3%) | -$15.99 M(-11.6%) |
| Dec 2023 | -$18.10 M(+2.9%) | -$3.44 M(-16.1%) | -$18.10 M(-0.6%) |
| Sept 2023 | - | -$4.11 M(-10.4%) | -$18.21 M(-8.1%) |
| June 2023 | - | -$4.58 M(-23.3%) | -$19.81 M(+0.9%) |
| Mar 2023 | - | -$5.97 M(+67.9%) | -$19.63 M(+11.6%) |
| Dec 2022 | -$17.59 M(+23.1%) | -$3.56 M(-37.7%) | -$17.59 M(-3.0%) |
| Sept 2022 | - | -$5.70 M(+29.7%) | -$18.13 M(+25.5%) |
| June 2022 | - | -$4.40 M(+11.8%) | -$14.45 M(+1.1%) |
| Mar 2022 | - | -$3.93 M(-3.9%) | -$14.30 M(0.0%) |
| Dec 2021 | -$14.30 M | -$4.10 M(+102.7%) | -$14.30 M(+28.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$2.02 M(-52.4%) | -$11.15 M(+23.2%) |
| June 2021 | - | -$4.25 M(+7.9%) | -$9.05 M(+88.3%) |
| Mar 2021 | - | -$3.93 M(+315.7%) | -$4.81 M(+325.8%) |
| Dec 2020 | -$1.13 M(+233.8%) | -$946.50 K(-1353.6%) | -$1.13 M(+540.2%) |
| Sept 2020 | - | $75.50 K(-2703.4%) | -$176.40 K(-31.8%) |
| June 2020 | - | -$2900.00(-98.9%) | -$258.70 K(-15.2%) |
| Mar 2020 | - | -$255.40 K(-4090.6%) | -$304.90 K(-9.8%) |
| Dec 2019 | -$338.30 K(-147.3%) | $6400.00(-194.1%) | -$338.20 K(-1.9%) |
| Sept 2019 | - | -$6800.00(-86.2%) | -$344.60 K(+2.0%) |
| June 2019 | - | -$49.10 K(-83.0%) | -$337.80 K(+17.0%) |
| Mar 2019 | - | -$288.70 K | -$288.70 K |
| Dec 2018 | $715.00 K | - | - |
FAQ
- What is Inhibikase Therapeutics annual free cash flow?
- What is the all time high annual FCF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual FCF year-on-year change?
- What is Inhibikase Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly FCF year-on-year change?
- What is Inhibikase Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM FCF year-on-year change?
What is Inhibikase Therapeutics annual free cash flow?
The current annual FCF of IKT is -$18.10 M
What is the all time high annual FCF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual free cash flow is $715.00 K
What is Inhibikase Therapeutics annual FCF year-on-year change?
Over the past year, IKT annual free cash flow has changed by -$504.90 K (-2.87%)
What is Inhibikase Therapeutics quarterly free cash flow?
The current quarterly FCF of IKT is -$4.88 M
What is the all time high quarterly FCF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly free cash flow is $75.50 K
What is Inhibikase Therapeutics quarterly FCF year-on-year change?
Over the past year, IKT quarterly free cash flow has changed by -$776.00 K (-18.90%)
What is Inhibikase Therapeutics TTM free cash flow?
The current TTM FCF of IKT is -$17.24 M
What is the all time high TTM FCF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM free cash flow is -$176.40 K
What is Inhibikase Therapeutics TTM FCF year-on-year change?
Over the past year, IKT TTM free cash flow has changed by +$968.30 K (+5.32%)